Please join me in my efforts to support the Dr. Marnie Rose Foundation through your support of team Blind Survivor!
John Jochetz passed away on December 30, 2020 at the age of 30 after living with Glioblastoma for nearly three and a half years. He was an avid supporter of Run for the Rose and the Dr. Marnie Rose Foundation. These are his reflections on his diagnosis written in 2020 for Team Blind Survivor. I welcome you to join us in participation this year and hopefully John provide us some warm weather and sunshine!
I was diagnosed with Grade 4 Glioblastoma Multiforme on September 1, 2017 at the age of 27. In September 5, 2017, I underwent a successful gross total resection (craniotomy) at M.D. Anderson Cancer Center in Houston, Texas. The positioning of my tumor cut off circulation to my optic nerves causing complete vision loss and total atrophy of my optic nerves within a span of six weeks. At this time there is no expectation I will regain my sight or light perception, but I am hopeful that research and time will yield beneficial medical advancements. I began radiation, chemotherapy, and immunotherapy treatment in October 2017 and completed treatment the following November 2018.
In November of 2019, after a year of my monitoring phase, scans showed tumor regrowth near my original surgical area. I agreed to undergo a second right frontal lobe craniotomy in December 2019 at M.D. Anderson Cancer Center. The surgery was successful, but impaired the use of my left hand. I am currently working to regain my strength and coordination and started chemotherapy in January 2020.
I continue to persevere, fight, and live my life with a positive outlook. I am determined to be a blind survivor!!
Thank you for visiting my team's page and spreading awareness about my fundraising!
The Dr. Marnie Rose Foundation:
The unwavering support from donors to the Dr. Marnie Rose Foundation has enabled the foundation to give more than $6.5 million over the past 17 years. Funds remain in Houston and are used immediately to enhance patient care.
• Clinical trials are started and expanded.
• Treatments are expedited from the laboratory to the patient.
• Brain cancer patients do not have the luxury of time.
Researchers receive immediate funding rather than waiting months or years. Our funds have led to extended survival for many patients.